Shin Nippon Biomedical Laboratories, Ltd. enters the 49th year since its foundation as the first Japanese contract research organization (CRO) in 1957. Since then, they have become able to support pharmaceutical companies with a full range of drug development services, including safety research, clinical pharmacology, and clinical trials. Currently, SNBL Group employs more than one thousand professionals and is the largest CRO in Japan.
SNBL Group has facilities and offices not only in Japan but also in the United States, Europe and China. The Group is proud of its world-ranking state-of-the-art facilities and technology that provide reliable support for research and drug development for a wide variety of diseases.
The Preclinical Research Operation boasts unparalleled experience and performance in scientific research for more than forty-five years. This operation division researches and extrapolates the safety of new drugs from many standpoints. Safety research is performed at the SNBL Research Facility in Kagoshima, Japan. The division also has a dedicated drug Pharmacokinetics and Bioanalysis Center in Wakayama, Japan. Experts in specialist fields of medical science covering toxicology, pharmacology, pathology, biochemistry, microbiology, genetic engineering, and drug metabolism pursue the assurance of new drug safety in all relevant fields. SNBL U.S.A., Ltd., located in the suburbs of Seattle, Washington, U.S.A., focuses on safety research for new drugs and plays a crucial role in SNBL Group's global strategies and operations.
In August 2004, SNBL CHINA, Ltd. was established in Gao Yao City, Guang Zhou Province, China to secure a stable source of research animals. The purpose of the company is to breed, develop, quarantine, and export primates. Over the years, SNBL has cultivated new markets and acquired unrivaled expertise and know-how for pharmaceutical development research using primates.
Contract business in the preclinical research industry is growing, as development processes are increasingly outsourced due to the fierce competition in pharmaceutical development. In order to ensure safety and efficacy of new biotechnology in humans, the demand for primates in pharmaceutical development is expected to increase.
SNBL has developed a network of primate sources in locations including China and Indonesia, but to provide higher-quality research animals and to secure a more stable source, SNBL CHINA, Ltd. was established. The establishment aims to provide SNBL in Japan and US, and other companies, a secure supply of the highest-quality primates. The basis of SNBL's portfolio strategy is the establishment of a comprehensive pharmaceutical development value chain from preclinical to clinical operations around the globe. SNBL CHINA, Ltd. will be not only be the headquarters of preclinical operations in China, but also a stepping stone to establishing clinical operations.